Want to see DTIL full AI Analyst Report?
DTIL Stock Chart & Stats
$8.49
-$0.04(-0.55%)
At close: 4:00 PM EDT
$8.49
-$0.04(-0.55%)
Day’s Range― - ―
52-Week Range$3.53 - $9.62
Previous Close$7.51
Volume250.62K
Average Volume (3M)253.18K
Market Cap
$159.26M
Enterprise Value$143.79M
Total Cash (Recent Filing)$87.55M
Total Debt (Recent Filing)$28.10M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 10, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.79
Shares Outstanding27,601,555
10 Day Avg. Volume256,458
30 Day Avg. Volume253,181
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit3.19
Enterprise Value/Ebitda-2.89
Forecast
1Y Price Target
$45.00Price Target Upside430.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.47
Revenue Forecast (FY)$13.43M
Bulls Say, Bears Say
Bulls Say
Clinical Program ProgressInitiating the first patient in a Phase 1/2 DMD gene-editing trial demonstrates tangible clinical execution for the ARCUS platform. The program’s regulatory designations may support development priority and improve the pathway toward future milestones if safety and efficacy are established.
Low Debt BurdenThe company’s low absolute debt relative to equity limits near-term leverage pressure and reduces interest-related constraints on capital allocation. This gives management more balance-sheet flexibility to direct available resources toward clinical development, although operating cash burn remains substantial.
Leadership RealignmentThe refreshed leadership structure clarifies responsibility across finance, customer-facing operations, research, and clinical development. Greater organizational focus could improve execution and stakeholder alignment as Precision advances multiple ARCUS-based programs through important clinical milestones.
Bears Say
Persistent Cash BurnSubstantial operating and free-cash-flow deficits show that the current business consumes significant cash to fund operations and development. If this pattern persists, Precision may need external capital, potentially limiting strategic flexibility and increasing dependence on financing conditions.
Unprofitable And Volatile ResultsNegative net income, EBIT, and EBITDA indicate that the business has not yet reached sustainable profitability. Revenue volatility further reduces earnings visibility, making it harder to fund development internally and increasing the importance of successful partnered or clinical programs.
Declining Shareholder EquityThe sharp reduction in equity reflects the cumulative effect of ongoing losses and weak returns on capital. A smaller equity base provides less financial cushion against continued development spending, reinforcing the need for disciplined cash management and eventual operating improvement.
Precision BioSciences News
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.53 and its highest was $9.62 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $159.26M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is Nov 10, 2026 which is in 22 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Aug 06, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$0.804 by -$0.456.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -0.85.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 27,601,555 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$1.26 in its last earnings report, missing expectations of -$0.804. Following the earnings report the stock price went down -0.669%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precision BioSciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (430.04% Upside)
$45.00 (430.04% Upside)
Blogger Sentiment
Bullish
DTIL Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 27.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.10%
12-Months-Change
Fundamentals
Return on Equity
-91.60%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Precision BioSciences
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
DTIL Stock 12 Month Forecast
Average Price Target
$45.00
▲(430.04% Upside)
Technical Analysis
Ownership Overview
2.79% Insiders
5.06% Mutual Funds
0.16% Other Institutional Investors
83.04% Public Companies and
Individual Investors